Biofrontera (BFRI)

• Market cap: $8.34M
• 1 day: 2.15%
• 5 days: 4.42%
• 1 month: -19.68%
• 3 months: -11.34%
• 6 months: -27.15%
• Year to date: -13.78%
• 1 year: -42.34%
• 5 years: -98.93%
• 10 years: -98.93%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Employees: 85

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

56% more funds holding

Funds holding: 9 [Q3] → 14 (+5) [Q4]

38% more capital invested

Capital invested by funds: $1.43M [Q3] → $1.97M (+$546K) [Q4]

3.98% more ownership

Funds ownership: 19.36% [Q3] → 23.35% (+3.98%) [Q4]